Cerapedics is an advanced orthobiologics company with i-FACTOR® Peptide Enhanced Bone Graft.
Among 400+ spinal bone grafts on the market, spine surgeons can feel confident in choosing i-FACTOR Peptide Enhanced Bone Graft which is backed by Level 1 human clinical data from an IDE study published in Spine and Neurosurgery. In this study i-FACTOR demonstrated high fusion rates and statistical superiority vs. autograft in overall clinical success.
One of only two Class III FDA-PMA approved spinal bone grafts, i-FACTOR is the leading evidence-based alternative and is powered by a first of its kind molecule called P-15: Osteogenic Cell Binding Peptide. i-FACTOR is free of many safety risks seen with other products such as ectopic bone formation and on average costs at least 30% less expensive than other drug-device combination products.
Among 400+ spinal bone grafts on the market, spine surgeons can feel confident in choosing i-FACTOR Peptide Enhanced Bone Graft which is backed by Level 1 human clinical data from an IDE study published in Spine and Neurosurgery. In this study i-FACTOR demonstrated high fusion rates and statistical superiority vs. autograft in overall clinical success.
One of only two Class III FDA-PMA approved spinal bone grafts, i-FACTOR is the leading evidence-based alternative and is powered by a first of its kind molecule called P-15: Osteogenic Cell Binding Peptide. i-FACTOR is free of many safety risks seen with other products such as ectopic bone formation and on average costs at least 30% less expensive than other drug-device combination products.
Location: United States, Colorado, Westminster
Employees: 51-200
Phone: +1 303-974-6275
Total raised: $89M
Founded date: 2001
Investors 1
| Date | Name | Website |
| - | KOFA Healt... | kofahealth... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 16.07.2018 | - | $22M | - |
| 19.04.2017 | - | $20M | - |
| 29.09.2016 | Series D | $11M | - |
| 07.04.2015 | - | $8M | - |
| 18.04.2014 | - | $9M | - |
| 12.12.2012 | Series C | $19M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Glen A. | Kashuba | Chief Exec... | linkedin.c... | - | g**n@cerap... |
Mentions in press and media 16
| Date | Title | Description |
| 05.06.2024 | Nucleus RadioPharma Secures Investment from AstraZeneca | What You Should Know: – Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca. – The strategic ... |
| 17.08.2021 | Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery | |
| 29.04.2021 | Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease | |
| 05.11.2020 | Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada | |
| 16.07.2018 | Orthobiologics Company Cerapedics Closes $22M Financing | Cerapedics, a Westminster, Colo.-based orthobiologics company, completed a $22m financing. The round was led by KCK Group. The company intends to use the funds to accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enha... |
| 19.04.2017 | Cerapedics Receives $20M Loan from Oxford Finance | Cerapedics, Inc., a Westminster, CO-based orthobiologics company engaged in the development and commercialization of bone graft substitute products for the treatment of orthopedic injuries, received a $20m senior secured term loan. Oxford F... |
| 29.09.2016 | Cerapedics Closed $11M Series D Financing | Cerapedics, a Westminster, Colo.-based orthobiologics company, completed an $11m in Series D financing. The backers were not disclosed. The company intends to use the funds to expand commercialization of i-FACTOR™ Peptide Enhanced Bone Graf... |
| 07.04.2015 | Cerapedics Raises $8M | Cerapedics, a Westminster, CO-based orthobiologics company, raised a total of $8m. This includes a $4m in equity financing from internal investors and a $4m term loan from GE Capital, Healthcare Financial Services. The company intends to us... |
| 21.04.2014 | GE gets behind Cerapedics and its i-FACTOR bone graft | Tech and healthcare giant GE (NYSE:GE) put some skin in Cerapedics and its i-FACTOR bone graft, funding a $9 million venture debt financing round for the Colorado-based company. Cerapedics plans to use the funds to make progress toward the ... |
| 18.04.2014 | Cerapedics Closes $9M Venture Debt Financing from GE Capital | Cerapedics, a Westminster, CO-based orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform, closed a $9m venture debt financing from GE Capital, Healthcare Financi... |
Show more